CureVac GmbH
Paul-Ehrlich-Str. 15
Tübingen
72076
Germany
Tel: 49-7071-92053-0
Fax: 49-7071-92053-11
Website: http://www.curevac.de/
58 articles with CureVac GmbH
-
San Diego-based Arcturus Therapeutics announced it was reassuming 100 percent of its global rights for ARCT-810, a messenger RNA (mRNA) drug to treat OTC Deficiency. The drug previously had a 50/50 collaboration between Arcturus and Tubingen, Germany-based CureVac AG.
-
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
-
Messenger RNA (mRNA) is a family of RNA molecules that transport genetic information from DNA to the ribosome, where it specifies the amino acid sequence that creates proteins. In theory, by coding your own mRNA, it should be possible to insert it into the cells and turn them into protein factori...
-
CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants Against RSV
1/8/2019
Important New Patent to Allow CureVac to Develop Vaccine Candidate for Neglected Respiratory Condition
-
BioNTech Inks $425 Million Collaboration Deal with Pfizer to Develop mRNA-based Flu Vaccines
8/16/2018
BioNTech, headquartered in Mainz, Germany, and Pfizer, based in New York City, signed a multi-year research-and-development deal to develop mRNA-based flu vaccines. -
CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA
3/22/2018
CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance to CureVac on GMP-conforming pharmaceutical manufacturing methods for producing RNA
-
CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria
2/13/2018
CureVac today announced the awarding of two new grants from the Bill & Melinda Gates Foundation.
-
CureVac Expands Intellectual Property Position That Significantly Improves Protein Expression for Its mRNA-Based Vaccines and Therapeutics
1/24/2018
CureVac announced that the United States Patent and Trademark Office and the European Patent Office have granted or respectively intend to grant multiple composition of matter patents for CureVac’s mRNA technology.
-
CureVac Highlights Key 2018 Corporate Milestones and Outlook
1/10/2018
CureVac AG today outlined key 2018 milestones in conjunction with its presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco.
-
A look at whether big money and big deals will be in store for 2018.
-
CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics
1/4/2018
Under the agreement, the companies will collaborate to develop up to four molecular therapy products for rare diseases using Curevac’s optimized natural mRNA sequence (RNAoptimizer) and Arcturus’s lipid-mediated nucleic acid delivery system (LUNAR).
-
Two of the top companies in the field are German-based CureVac and U.S.-based Moderna Therapeutics.
-
CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics
10/30/2017
The novel production facility - called GMP IV - will be able to produce approximately 30 million doses of RNA-based therapeutics per year, and is expected to be fully commissioned in 2019.
-
CureVac Initiates Phase I Clinical Trial of RNAdjuvant Candidate As Intratumoral Therapy for Solid Tumors
10/27/2017
CureVac today announced it has initiated a Phase I study assessing the intratumoral application of its novel RNAdjuvant technology in patients with superficial solid tumors that are easily accessible for repeated intratumoral injections.
-
George Scangos' Bold Vision
10/25/2017
The former Biogen CEO is making waves at his new venture, Vir Biotechnology. -
Publication in npj Vaccines Demonstrates CureVac's RNActive Vaccine is Superior to Licensed Vaccines
10/23/2017
CureVac today announced the publication of a study in the peer-reviewed journal, Nature Partner Journals Vaccines, demonstrating that vaccines based on CureVac's sequence optimized, chemically unmodified mRNA formulated in optimized LNPs are highly immunogenic and well tolerated.
-
Eli Lilly has signed a collaboration deal with CureVac that could total up to $1.8B.
-
Publication In EMBO Molecular Medicine Demonstrates CureVac’s Proprietary Mrna Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins And Tumors
8/16/2017
-
Publication In EMBO Molecular Medicine Demonstrates CureVac's Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins And Tumors
8/15/2017
-
CureVac Announces Publication In The Lancet Of First-Ever Human Proof-Of-Concept Study Investigating The Safety And Immunogenicity Of A Prophylactic mRNA Vaccine
7/26/2017